预约演示
更新于：2025-07-16
Bimatoprost
贝美前列素
更新于：2025-07-16
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H37NO4 |
InChIKeyAQOKCDNYWBIDND-FTOWTWDKSA-N |
CAS号155206-00-1 |
关联
150
项与 贝美前列素 相关的临床试验IRCT20190210042676N36
Evaluation of safety and efficacy profile of the eyelash booster solution containing stemoxydine and bimatoprost on women with hypotrichosis
CTIS2023-504759-28-00
RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES. - BIM-001
NCT06267274
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
100 项与 贝美前列素 相关的临床结果
登录后查看更多信息
100 项与 贝美前列素 相关的转化医学
登录后查看更多信息
100 项与 贝美前列素 相关的专利（医药）
登录后查看更多信息
1,145
项与 贝美前列素 相关的文献（医药）2025-08-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation
Article
作者: Kim, Hyun-Kyung ; Sung, Min Kyung ; Shin, Eun Jin ; Kim, Hyung Soo ; Woo, In Suk ; Han, Kyoung-Moon ; Kim, You Kyung
Some prostaglandin F2α (PGF2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. However, research on the simultaneous analysis of multiple PGF2α analogs using HPLC-UV or DAD techniques is limited. In this study, a high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of 11 PGF2α analogs, optimizing both the analytical column and sample preparation method. Five columns with varying particle sizes, lengths, and packing types were compared to select the optimal analytical column. The separation efficiency of the columns was confirmed by comparing their chromatographic parameters, including retention time, resolution, number of theoretical plates, and height equivalent to a theoretical plate. Solid-phase extraction (SPE) was used to pretreat cosmetic samples, and the washing solvent and cartridge type for the SPE process were optimized. The established HPLC method was validated in terms of linearity, limits of detection and quantification, recovery, accuracy, and precision. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF2α analogs.
2025-07-01CURRENT ORGANIC SYNTHESIS
Synthesis, Characterization, and Docking Studies of 1,4-dien as a Potential Impurity in Bimatoprost Drug
Article
作者: Guttikonda, Nagarjuna Reddy ; Haridasyam, Sharath Babu ; Venkatanarayana, Muvvala
Introduction::
Bimatoprost synthesis, novel diene impurity, Pd/C, Docking studies, IFD calculations, prostaglandin.
Methods::
This impurity was controlled by employing 30% Pd/C, and the impurity level was brought to the permissible level, i.e., 0.03% (ICH guidelines) in the final drug preparation of Bimatoprost.
Results::
Finally, induced-fit docking calculations were performed to theoretically evaluate the binding efficiencies of these inhibitors in the crystal structure of Prostaglandin F syn-thase (PGFS).
Conclusion::
There are negligible differences in RMSD and docking scores between the two ligands, which amount to only 0.18 Å and 0.313 kcal/mol, respectively. These findings strongly indicate that both ligands are likely to exhibit similar biological functions and effi-ciencies.
2025-07-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Adherence and Persistence on Prostaglandin Analogues for Glaucoma: A Systematic Review and Meta-Analysis
Review
作者: Baudouin, Christophe ; Myers, Jonathan S ; Evans, Jennifer S ; Martinez-de-la-Casa, Jose ; Van Tassel, Sarah H ; Goyal, Nina A ; Ng, Alvin
PURPOSE:
To systematically review, synthesize and quantify studies reporting patterns of adherence and persistence with prostaglandin analogues (PGAs) in order to comprehensively understand real-world treatment behavior among patients with glaucoma who are prescribed PGAs. These data can inform the decision between a glaucoma therapy based on either topical PGA medications or procedural PGA-based intervention.
DESIGN:
Systematic literature review (SLR) and meta-analysis (MA).
METHODS:
We updated a 2011 SLR using electronic database searches (MEDLINE, Embase and the Cochrane Database of Systematic Reviews [CDSR]), supplemented by hand searches of SLR and MA bibliographies. We included observational studies conducted in adult glaucoma patients treated with PGAs that reported objective measures of persistence or adherence. In addition to estimated rates of adherence and persistence, adherence among patients on any/unspecified PGA was characterized by mean MPR/PDC (medication possession ratio/proportion of days covered, where values >80% indicate good adherence). Duration of therapy was defined as the time period between initial therapy prescription and time of therapy discontinuation or switch.
RESULTS:
The SLR included 50 publications reporting on 47 unique studies and involving 961,000 patients. The subsequent MA included all but four studies which did not report the age distribution of patients. The mean proportion of patients on any/unspecified PGA who were adherent at Year 1 was 44% (95% CI: 31%-58%). Among patients on any/unspecified PGA, the mean MPR/PDC was 54% (95% CI: 38%-75%) at Year 1 and 60% at Year 2 (95% CI: 39%-94%). The mean proportion of patients on any/unspecified PGA who were persistent fell from 75% (95% CI: 66%-85%) at Month 6 to 31% (95% CI: 12%-55%) at Year 3, with a smaller decrease observed between Year 1 (56%; 95% CI: 45%-66%) and Year 2 (53%; 95% CI: 45%-62%), and a larger decrease between Years 2 and 3. The mean duration on therapy was 315.7 days (95% CI: 190.0%-441.5 days).
CONCLUSIONS:
Suboptimal adherence and persistence with PGAs are common, with further decreases as duration lengthens. These findings may underscore the value of procedural glaucoma treatments that do not depend on daily patient engagement with topical medications.
100 项与 贝美前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2009-07-07 | |
| 青光眼 | 日本 | 2009-07-07 | |
| 少毛症 | 美国 | 2008-12-24 | |
| 开角型青光眼 | 美国 | 2001-03-16 | |
| 高眼压症 | 美国 | 2001-03-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 水眼 | 临床3期 | 美国 | 2011-09-01 | |
| 水眼 | 临床3期 | 法国 | 2011-09-01 | |
| 水眼 | 临床3期 | 意大利 | 2011-09-01 | |
| 水眼 | 临床3期 | 菲律宾 | 2011-09-01 | |
| 水眼 | 临床3期 | 中国台湾 | 2011-09-01 | |
| 水眼 | 临床3期 | 英国 | 2011-09-01 | |
| 脱发 | 临床3期 | 日本 | 2011-07-01 | |
| 白内障 | 临床2期 | 美国 | 2023-10-13 | |
| 雄激素脱发 | 临床2期 | 美国 | 2011-06-01 | |
| 雄激素脱发 | 临床2期 | 德国 | 2011-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 441 | 壓製齋簾憲蓋窪鑰鑰膚(夢鏇壓糧鑰願餘選構憲) = 憲蓋觸鹽築顧顧鑰構選 醖觸衊鏇艱獵範遞壓衊 (廠憲製蓋顧鏇壓製網顧, 369 ~ 485) 更多 | 积极 | 2025-02-22 | |||
临床2期 | - | LL-BMT1 32-µg dose | 選醖積憲顧鑰糧夢衊鏇(膚鑰範齋遞鬱遞築網窪) = 憲餘餘選鏇齋範積糧艱 夢壓鹹鏇餘醖淵壓鏇糧 (網顧繭糧衊構艱構遞構 ) 更多 | 积极 | 2024-11-12 | ||
bimatoprost 0.01% | - | ||||||
临床3期 | 485 | (T4032) | 範繭醖鹽鬱鹹窪窪構壓(壓製簾選鹹築鹹淵窪獵) = 餘選願製遞製顧鏇網廠 繭憲構鹹淵範壓鑰膚繭 (範觸顧憲選憲齋繭築製, 0.19) 更多 | - | 2023-11-21 | ||
(Lumigan®) | 範繭醖鹽鬱鹹窪窪構壓(壓製簾選鹹築鹹淵窪獵) = 鏇齋製鏇構鏇觸醖醖鬱 繭憲構鹹淵範壓鑰膚繭 (範觸顧憲選憲齋繭築製, 0.18) 更多 | ||||||
临床3期 | 37 | (Bimatoprost SR 10 μg) | 鏇糧觸襯願鹹範窪衊糧(廠窪顧窪壓膚鹹網淵醖) = 齋艱製淵鹽鹽夢顧糧遞 獵鹹淵簾廠齋構構願鏇 (繭醖艱築簾膚窪鹽繭夢, 5.65) 更多 | - | 2023-06-08 | ||
(LUMIGAN 0.01%) | 鏇糧觸襯願鹹範窪衊糧(廠窪顧窪壓膚鹹網淵醖) = 淵蓋糧廠糧構淵觸顧鏇 獵鹹淵簾廠齋構構願鏇 (繭醖艱築簾膚窪鹽繭夢, 5.27) 更多 | ||||||
临床3期 | - | 觸淵艱鑰蓋願膚鑰鑰遞(蓋獵艱壓膚顧製鑰繭簾) = 選鏇憲範艱夢鹽遞窪窪 齋構壓窪襯醖願淵襯觸 (鑰糧積餘顧襯構選積鹽 ) | - | 2022-05-28 | |||
觸淵艱鑰蓋願膚鑰鑰遞(蓋獵艱壓膚顧製鑰繭簾) = 鑰憲簾膚窪顧構餘膚艱 齋構壓窪襯醖願淵襯觸 (鑰糧積餘顧襯構選積鹽 ) | |||||||
N/A | 122 | Bimatoprost SR | 廠艱衊繭膚築膚壓繭淵(淵壓獵繭蓋顧遞憲壓衊) = 鬱鬱築鹹製鹽餘簾壓鬱 衊網鏇膚鹹醖願鏇糧簾 (鬱淵窪衊齋鏇壓範獵衊 ) | - | 2022-05-01 | ||
临床3期 | 203 | 網窪蓋蓋醖窪願範製艱(鹹願齋襯鹹膚壓夢壓淵) = 簾窪膚廠願艱鬱鬱醖範 構醖簾積壓獵廠壓範淵 (鑰夢艱構壓製簾網廠鏇 ) | - | 2022-05-01 | |||
N/A | - | - | Bimatoprost free acid | 選蓋鑰遞鹽襯鑰積築襯(餘範糧積簾齋齋遞衊壓) = a dose-dependent although non-statistically significant increase in protein expression with a maximal increase of 56% 艱蓋蓋遞壓鑰窪觸膚蓋 (窪鏇艱積願製蓋築醖齋 ) 更多 | - | 2022-05-01 | |
N/A | 122 | Bimatoprost SR implantation | 襯網廠鹽廠鑰鹹製糧繭(蓋襯範簾蓋簾糧構淵艱) = 憲膚夢膚簾鹹築網積鹹 膚夢獵淵鹹壓繭蓋衊餘 (築齋窪衊觸構蓋艱鏇廠 ) | - | 2022-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用